These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36299620)

  • 1. Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study.
    Spyropoulos AC; Raskob GE; Spiro TE; Lu W; De Sanctis Y; Albanese J; Mebazaa A; Barnathan ES
    TH Open; 2022 Oct; 6(4):e304-e308. PubMed ID: 36299620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
    Raskob GE; Spyropoulos AC; Spiro TE; Lu W; Yuan Z; Levitan B; Suh E; Barnathan ES
    J Am Heart Assoc; 2021 Nov; 10(22):e021579. PubMed ID: 34755519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
    Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos A; Tapson V
    J Thromb Thrombolysis; 2011 May; 31(4):407-16. PubMed ID: 21359646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
    N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
    Spyropoulos AC; Raskob GE; Cohen AT; Ageno W; Weitz JI; Spiro TE; Lu W; Lipardi C; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard G; Steg PG; Sugarmann C; Barnathan ES
    Circulation; 2022 May; 145(19):1471-1479. PubMed ID: 35389229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.
    Lipardi C; Elliott CG; Sugarmann CL; Haskell L; Spyropoulos AC; Raskob GE; Xu J; Lu W; Marsigliano J; Spiro T; Yuan Z; Wu S; Barnathan ES
    Clin Appl Thromb Hemost; 2021; 27():10760296211053316. PubMed ID: 34719984
    [No Abstract]   [Full Text] [Related]  

  • 7. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
    N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
    Levitan B; Yuan Z; Turpie AG; Friedman RJ; Homering M; Berlin JA; Berkowitz SD; Weinstein RB; DiBattiste PM
    Vasc Health Risk Manag; 2014; 10():157-67. PubMed ID: 24707185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
    Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P;
    N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
    Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
    Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
    N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
    Weitz JI; Raskob GE; Spyropoulos AC; Spiro TE; De Sanctis Y; Xu J; Lu W; Suh E; Argenti D; Yang H; Albanese J; Lipardi C; Barnathan ES
    Thromb Haemost; 2020 Mar; 120(3):515-524. PubMed ID: 31975354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
    Burness CB; Perry CM
    Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
    Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
    J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.
    Liew AY; Piran S; Eikelboom JW; Douketis JD
    J Thromb Thrombolysis; 2017 Apr; 43(3):291-301. PubMed ID: 27900627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
    Albertsen IE; Larsen TB; Rasmussen LH; Overvad TF; Lip GY
    Drugs; 2012 Sep; 72(13):1755-64. PubMed ID: 22876779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
    Spyropoulos AC; Lipardi C; Xu J; Lu W; Suh E; Yuan Z; Levitan B; Sugarmann C; De Sanctis Y; Spiro TE; Barnathan ES; Raskob GE
    Clin Appl Thromb Hemost; 2019; 25():1076029619886022. PubMed ID: 31746218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis.
    Huang HF; Li SS; Yang XT; Xie Q; Tian XB
    Medicine (Baltimore); 2018 Nov; 97(48):e13465. PubMed ID: 30508972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.